Consult your GP if pain is severe, persistent, or accompanied by swelling, redness, fever, or significantly affects daily activities
Tirzepatide deep-dive Tirzepatide is made by Eli Lilly under two brand names: Mounjaro -- weekly injection, FDA-approved for type 2 diabetes in 2022 (doses 2.5 mg through 15 mg) Zepbound -- weekly injection, FDA-approved for chronic weight management in November 2023 [4] The headline trial is SURMOUNT-1: 2,539 adults without diabetes, BMI of 30 or higher (or 27 with a weight-related condition), randomized across three tirzepatide doses (5, 10, 15 mg) versus placebo for 72 weeks
Refrigerated after reconstituted
Tirzepatide BNF NICE
Clinical trials show that dizziness affects approximately 510% of people using semaglutide, tirzepatide, and other GLP-1 agents